Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.48 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6099521 | 1.00 | ALDH1A1 (0.49) | ALDH1A1LMNAHTTSMN1; SMN2UGT2B7 | |
| SCHEMBL20238211 | 1.00 | ALDH1A1 (0.49) | ALDH1A1LMNAHTTSMN1; SMN2UGT2B7 | |
| SCHEMBL11628125 | 0.85 | AHR (0.58) | ALDH1A1LMNAHTTSMN1; SMN2AHR | |
| SCHEMBL20604354 | 0.82 | SLC6A2 (0.46) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A4 | |
| SCHEMBL20604406 | 0.82 | SLC6A2 (0.46) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A4 | |
| SCHEMBL11789449 | 0.82 | TSHR (0.48) | ALDH1A1LMNAHTTUGT2B7CYP3A4 | |
| SCHEMBL19414246 | 0.82 | UGT2B7 (0.45) | ALDH1A1LMNAUGT2B7SLC6A4SLC6A2 | |
| SCHEMBL20604356 | 0.82 | SLC6A2 (0.46) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A4 | |
| SCHEMBL19667832 | 0.82 | PDE2A (0.56) | ALDH1A1LMNAHTTSMN1; SMN2UGT2B7 | |
| Hydrogen Peroxide SCHEMBL10347735 | 0.81 | ALDH1A1 (0.49) | ALDH1A1LMNAHTTSMN1; SMN2AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187741-B2 | Glycosidase inhibitors | ASCENEURON SA (CH) | 2025-01-07 | — | — | US | disclosed |
| CN-111848412-B | Method for efficiently realizing N-alkylation reaction by using cycloiridium catalyst | 赣南医学院 | 2023-05-12 | — | — | CN | disclosed |
| CN-115590966-A | Therapeutic combinations of drugs and methods of use thereof | 康圣博施医药有限公司（US） | 2023-01-13 | — | — | CN | disclosed |
| US-20220411440-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-12-29 | — | — | US | disclosed |
| CN-115350184-A | Therapeutic combinations of drugs and methods of use thereof | 康圣博施医药有限公司 | 2022-11-18 | — | — | CN | disclosed |
| CN-115304595-A | Therapeutic combinations of drugs and methods of use thereof | 康圣博施医药有限公司 | 2022-11-08 | — | — | CN | disclosed |
| CN-110325531-B | Benzenesulfonamides and their use as therapeutic agents | 泽农医药公司 | 2022-05-27 | — | — | CN | disclosed |
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2021-11-16 | — | — | US | disclosed |
| CN-107108601-B | Glycosidase inhibitors | 阿森纽荣股份公司 | 2021-08-20 | — | — | CN | disclosed |
| CN-109384645-B | Method for synthesizing secondary alcohol | 南京理工大学 | 2021-08-03 | — | — | CN | disclosed |
| EP-0885889-A2 | Process for the preparation of pyrazole-3-carboxylic acids | SANOFI (FR) | 1998-12-23 | — | — | EP | disclosed |
| EP-0598750-A1 | INDOLES | Pfizer Limited (GB) | 1994-06-01 | — | — | EP | disclosed |
| EP-0355351-B1 | Process for the preparation of amines | BAYER AG (DE) | 1993-11-10 | — | — | EP | disclosed |
| WO-1993002050-A1 | INDOLES | PFIZER LIMITED (GB) | 1993-02-04 | — | — | WO | disclosed |
| US-5011996-A | Process for the preparation of amines | BAYER AKTIENGESELLSCHAFT (DE) | 1991-04-30 | — | — | US | disclosed |
| EP-0355351-A2 | Process for the preparation of amines | BAYER AG (DE) | 1990-02-28 | — | — | EP | disclosed |
| EP-0093010-B1 | ALPHA-HYDROXYETHYLPHOSPHINATES, AND THEIR PRODUCTION AND USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1986-06-11 | — | — | EP | disclosed |
| US-4554111-A | α-Hydroxyethylphosphinates, and their production and use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-11-19 | — | — | US | disclosed |
| US-4544652-A | α-Hydroxyethylphosphinates, and their use as fungicides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-10-01 | — | — | US | disclosed |
| EP-0093010-A2 | Alpha-hydroxyethylphosphinates, and their production and use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411440-A1 | GLYCOSIDASE INHIBITORS | GAA, ENGASE, GBA3 | ALDH1A1 778/4885LMNA 1184/4885HTT 455/4885 |
| US-12187741-B2 | Glycosidase inhibitors | GAA, ENGASE, GBA3 | ALDH1A1 778/4885LMNA 1184/4885HTT 455/4885 |
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | KCND2, SCN1A, CACNA1D | ALDH1A1 2649/4885LMNA 1478/4885HTT 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.